Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Contribution of Substance P to Blood Pressure Regulation in the Setting of Dipeptidyl Peptidase IV (DPP4) and Angiotensin-Converting Enzyme (ACE) Inhibition

NCT02130687 is registered in ClinicalTrials.gov with Vanderbilt University as lead sponsor.

NCT NCT02130687
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02130687 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Contribution of Substance P to Blood Pressure Regulation in the Setting of Dipeptidyl Peptidase IV (DPP4) and Angiotensin-Converting Enzyme (ACE) Inhibition
Lead sponsor
Vanderbilt University
Phase
Not applicable
Overall status
Completed
Start date
June 30, 2014
Completion date
August 31, 2020
Enrollment
106 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hypertension, type 2 diabetes mellitus